Cisplatin Delivery
Cisplatin Delivery - Related Videos
07:47
Custom-designed Laser-based Heating Apparatus for Triggered Release of Cisplatin from Thermosensitive Liposomes with Magnetic Resonance Image Guidance
0 Views •
Cited by 17 •
2015
AN MRI-compatible custom-designed laser-based heating apparatus has been developed to provide local heating of subcutaneous tumors in order to activate release of agents from thermosensitive liposomes specifically at the tumor region.
13:25
Acute Kidney Injury Model Induced by Cisplatin in Adult Zebrafish
0 Views •
Cited by 10 •
2021
This protocol describes the procedures to induce Acute Kidney Injury (AKI) in adult zebrafish using cisplatin as a nephrotoxic agent. We detailed the steps to evaluate the reproducibility of the technique and two techniques to analyze inflammation and cell death in the renal tissue, flow cytometry and TUNEL, respectively.
04:20
Knockdown of FAM83A to Verify Its Role in Cervical Cancer Cell Growth and Cisplatin Sensitivity
0 Views •
2024
Here, we show the procedures for FAM83A knockdown; the assays to detect its effects on proliferation, migration, and invasion of cervical cancer cells; and the sensitization of these cells to cisplatin. This study provides a promising target gene for cervical cancer and a reference for further drug research.
06:30
Intraductal Delivery to the Rabbit Mammary Gland
0 Views •
Cited by 9 •
2017
Here, we describe a technique for the localized delivery of reagents to the rabbit mammary gland via an intraductal injection. In addition, we describe a protocol for visualization and the confirmation of delivery by high-resolution ultrasound imaging of contrast agents.
08:02
Cell Squeezing as a Robust, Microfluidic Intracellular Delivery Platform
0 Views •
Cited by 40 •
2013
Rapid mechanical deformation of cells has emerged as a promising, vector-free method for intracellular delivery of macromolecules and nanomaterials. This protocol provides detailed steps on how to use the system for a broad range of applications.
FAQs
Carrier design can alter when and where cisplatin becomes available to cancer cells. A system may improve tumor accumulation, promote cellular uptake, or provide controlled release after reaching the intended site. These changes matter because cisplatin must enter cancer cells and form DNA crosslinks; delivery therefore connects transport behavior with replication disruption and cell death.
Limiting healthy-tissue exposure is a central design objective because cisplatin’s therapeutic performance depends not only on its anticancer activity but also on where the drug distributes. Bioengineered carriers can modify biodistribution, concentrating delivery-related effects toward tumors while reducing unnecessary exposure elsewhere. This balance addresses dose-limiting toxicity without changing the underlying DNA-crosslinking action.
Nanoparticles, targeted carriers, hydrogels, and localized delivery platforms address different transport problems. Nanoparticles and other carriers can support altered distribution, uptake, or release, whereas hydrogels and localized systems emphasize delivery at a selected site. The relevant distinction is not simply material type, but which limitation the design targets, such as poor accumulation, limited stability, or uncontrolled release.
Key performance variables include drug stability, tumor accumulation, cellular uptake, release control, biodistribution, and toxicity. Improving one feature does not automatically optimize the others, so cisplatin delivery systems are evaluated as integrated designs. Controlled release is valuable only if the drug can reach the tumor and become available to cancer cells at the intended site.
Design work generally begins by matching a delivery platform to the therapeutic limitation being addressed. Researchers can then engineer a system around targeted transport, localized placement, or controlled release while considering stability and distribution. The resulting design is judged by whether it improves tumor delivery, supports cellular uptake, and reduces unwanted tissue exposure rather than by carrier choice alone.
In bioengineering, cisplatin delivery serves as a model for developing precision drug-delivery technologies for cancer treatment. Research outcomes are framed around improved accumulation, more controlled drug release, better tumor exposure, reduced dose-limiting toxicity, and potential help with resistance. These goals make the topic relevant both to chemotherapy optimization and to broader engineering of disease-focused pharmaceutical systems.